Andreessen Horowitz's shiny, new $15 billion reveals where the firm sees the biggest opportunities.

The article discusses Andreessen Horowitz's recent fundraising of over $15 billion, highlighting the firm's evolution into a prominent and sometimes controversial player in the venture capital landscape since its founding in 2009. The funds will be allocated across various initiatives, including a $6.75 billion growth fund, a $700 million biotech and healthcare fund, and significant investments in defense technology and other venture strategies. The firm aims to invest in technology that is competitive with China, reflecting a geopolitical dimension to its strategy. The article also contextualizes this fundraising within the broader trend of increasing capital in the venture capital sector, particularly in response to the AI boom. [Extracted from the article]